<DOC>
	<DOCNO>NCT01162031</DOCNO>
	<brief_summary>We hope learn clinical efficacy bortezomib T-cell prolymphocytic leukemia . Patients select possible participant study bone marrow disorder know T-cell prolymphocytic leukemia ( T-cell PLL ) tend respond well conventional treatment chemotherapy .</brief_summary>
	<brief_title>Phase II Study VELCADE Relapsed Refractory T-cell Prolymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Bilirubin : &lt; 2.0 x Upper limit normal ( ULN ) / Alanine Transaminase ( ALT ) : &lt; 3.0 x ULN ( &lt; 5x ULN hepatic compromise present ) . Eastern Cooperative Group ( ECOG ) 02 . Confirmed diagnosis Tcell PLL accord WHO classification . Confirmed prior therapy subject document either refractory relapse since treatment first document response . Patients meet follow exclusion criterion enrol study . Patient platelet count &lt; 30 ' 10 9/L within 14 day enrollment . Patient absolute neutrophil count &lt; 1.0 ´ 10 9/L within 14 day enrollment . Patient ³Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum bhuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 14 day enrollment . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patients uncontrolled intercurrent illness , active uncontrolled infection , fever &gt; 38.5c day schedule dosing . Patients serious illness , medical condition , medical history , include laboratory result , , investigator 's opinion , would likely interfere patient 's participation study , interpretation result . Any condition ( e.g. , know suspected poor compliance , psychological instability , geographical location , etc ) , judgment investigator , may affect patient 's ability sign inform consent undergo study procedure . Any condition put patient undue risk discomfort result adherence study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>